SEC-sourced researchBeta
BVS
Bioventus Inc.
Company comparison ↗
Data passport
- CIK
- 0001665988
- Exchange
- Nasdaq
- Business activity
- — · SIC 3841
- Financial inputs
- 6/6
- Filing date
- Mar 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 512,345,000.0000 | Mar 5, 2026 |
| December 2024 | 573,280,000.0000 | Mar 5, 2026 |
| December 2025 | 568,087,000.0000 | Mar 5, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 568,087,000.0000 | 22,732,000.0000 | 74,673,000.0000 | 683,559,000.0000 | 455,112,000.0000 | Mar 5, 2026 |
| December 2024 | 573,280,000.0000 | -36,125,000.0000 | 38,795,000.0000 | 727,956,000.0000 | 542,352,000.0000 | Mar 5, 2026 |
| December 2023 | 512,345,000.0000 | -156,230,000.0000 | 15,344,000.0000 | — | — | Mar 5, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $568.09M | December 2025 | Mar 5, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $573.28M | December 2024 | Mar 5, 2026 | 10-K |
| Net incomeNetIncomeLoss | $22.73M | December 2025 | Mar 5, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $74.67M | December 2025 | Mar 5, 2026 | 10-K |
| Total assetsAssets | $683.56M | December 2025 | Mar 5, 2026 | 10-K |
| Total liabilitiesLiabilities | $455.11M | December 2025 | Mar 5, 2026 | 10-K |